All the news Showing 10 of 40 articles from: Side effectsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Women with HCV postmenopause may experience insulin resistance Healio Hepatology / 26 January 2016 Cardiovascular disease risk is higher for people with hepatitis C Keith Alcorn / 20 January 2016 People with hepatitis C are at higher risk of dying from cardiovascular disease, suffering a stroke or developing cardiovascular problems than people with similar risk factors for heart disease who ... Rare life-threatening toxicities emerge as real-world use of hepatitis C drugs grows Keith Alcorn / 12 November 2015 The US Food and Drug Administration has issued a warning that Viekira Pak and Technivie can cause “serious liver injury” mainly in patients with underlying advanced liver disease, following a small number of ... Viekira Pak, Technivie May Up Serious Liver Injury Risk: FDA Medscape / 23 October 2015 Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy HIVandHepatitis.com / 29 June 2015 A more personalised approach to hepatitis C treatment may improve adherence and completion rates Roger Pebody / 09 March 2015 People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as an important facilitator of good adherence. ... Deaths of Japanese patients prompt label change for simeprevir HCP Live / 24 November 2014 After Patient's Death, Study Shows HCV Drug Cardiotoxic in 14 of 34 Treated Patients Medscape (requires registration) / 29 September 2014 AbbVie 3D hepatitis C regimen is well-tolerated in phase 3 trials Liz Highleyman / 22 September 2014 AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the phase 3 SAPPHIRE trials, according to a pooled analysis presented at the 54th Interscience Conference ... Low lymphocyte count a risk factor for infections for people taking HCV therapy Michael Carter / 15 January 2014 A low lymphocyte count is associated with an increased risk of infections during hepatitis C virus (HCV) treatment that includes pegylated interferon and ribavirin, according to the results of a large observational study ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive